Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 15/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 15/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 15/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 15/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 8/20 | 1.00 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.45 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.45 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formaldehyde SCHEMBL27875050 | 0.94 | GABRG2 (0.88) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL4856668 | 0.90 | GABRG2 (0.81) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL4855823 | 0.85 | GABRG2 (0.72) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2653543 | 0.84 | GABRG2 (0.71) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2653507 | 0.83 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2654763 | 0.83 | GABRG2 (0.70) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL21117486 | 0.82 | GABRG2 (0.68) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL21117352 | 0.82 | GABRG2 (0.68) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2653411 | 0.80 | GABRG2 (0.66) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2654488 | 0.80 | GABRG2 (0.67) | GABRG2GABRB3GABRA5GABRA3GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235021-A1 | Phenylpyridazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2006-10-19 | — | — | US | claimed |
| CN-109970806-B | Organic metal iridium complex, preparation method thereof and application thereof in OLED | 中节能万润股份有限公司 | 2021-08-13 | — | — | CN | disclosed |
| US-10833276-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2020-11-10 | — | — | US | disclosed |
| US-10777754-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2020-09-15 | — | — | US | disclosed |
| US-9997712-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2018-06-12 | — | — | US | disclosed |
| US-9997712-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2018-06-12 | — | — | US | disclosed |
| US-20180145262-A1 | Organic Electroluminescent Materials and Devices | UNIVERSAL DISPLAY CORPORATION | 2018-05-24 | — | — | US | disclosed |
| US-20180145262-A1 | Organic Electroluminescent Materials and Devices | UNIVERSAL DISPLAY CORPORATION | 2018-05-24 | — | — | US | disclosed |
| US-9780316-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2017-10-03 | — | — | US | disclosed |
| US-9780316-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2017-10-03 | — | — | US | disclosed |
| US-20100317665-A1 | Anti-Inflammatory And Protein Kinase Inhibitor Compositions And Related Methods For Downregulation Of Detrimental Cellular Responses And Inhibition Of Cell Death | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-16 | — | — | US | disclosed |
| EP-1532120-B1 | PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2009-01-14 | — | — | EP | disclosed |
| US-20060235021-A1 | Phenylpyridazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2006-10-19 | — | — | US | disclosed |
| US-20060073472-A1 | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death | UNIVERSITE DE STRASBOURG (FR) | 2006-04-06 | — | — | US | disclosed |
| EP-1532120-A1 | PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2005-05-25 | — | — | EP | disclosed |
| EP-1430033-A4 | ANTI-INFLAMMATORY AND PROTEIN KINASE INHIBITOR COMPOSITION AND METHOD OF USE | UNIV NORTHWESTERN (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1430033-A1 | ANTI-INFLAMMATORY AND PROTEIN KINASE INHIBITOR COMPOSITION AND METHOD OF USE | NORTHWESTERN UNIVERSITY (US) | 2004-06-23 | — | — | EP | disclosed |
| WO-2004014865-A1 | PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
| US-20030176437-A1 | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-09-18 | — | — | US | disclosed |
| WO-2003018563-A1 | ANTI-INFLAMMATORY AND PROTEIN KINASE INHIBITOR COMPOSITION AND METHOD OF USE | NORTHWESTERN UNIVERSITY (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10833276-B2 | Organic electroluminescent materials and devices | OCIAD2, OCIAD1, TYR | GABRG2 3781/4885GABRB3 2021/4885GABRA5 2679/4885 |
| US-20060235021-A1 | Phenylpyridazine derivatives as ligands for gaba receptors | GABRA5, GABRA2, GABRA3 | GABRG2 20/4885GABRB3 8/4885GABRA5 1/4885 |
| US-20060073472-A1 | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death | CASP2, CASP1, DAPK2 | GABRG2 4521/4885GABRB3 4152/4885GABRA5 4414/4885 |
| US-20180145262-A1 | Organic Electroluminescent Materials and Devices | OCIAD2, OCIAD1, TYR | GABRG2 3781/4885GABRB3 2021/4885GABRA5 2679/4885 |
| US-20030176437-A1 | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death | CASP2, CASP1, DAPK2 | GABRG2 4521/4885GABRB3 4152/4885GABRA5 4414/4885 |
| US-20100317665-A1 | Anti-Inflammatory And Protein Kinase Inhibitor Compositions And Related Methods For Downregulation Of Detrimental Cellular Responses And Inhibition Of Cell Death | CASP2, CASP1, DAPK2 | GABRG2 4521/4885GABRB3 4152/4885GABRA5 4414/4885 |
| US-10777754-B2 | Organic electroluminescent materials and devices | DBF4, ORC3, NUDC | GABRG2 1788/4885GABRB3 1432/4885GABRA5 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.